Cempra (CEMP) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cempra (CEMP): Two Key Upcoming Catalysts - Needham
October 25, 2016 8:24 AM EDTNeedham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Cempra, Inc. (NASDAQ: CEMP) ahead of the FDA Advisory Committee (AdCom) meeting scheduled for 11/4/16 where the Solithera NDA will be reviewed.
Cempra announced positive efficacy results from two Phase 3 trials (SOLITAIRE-Oral and... More
